FIELD: biotechnology.
SUBSTANCE: invention relates to a humanized single-domain antibody to IL-4Rα, the method of its preparation, as well as the fusion protein and the medicinal product containing it. The following is also disclosed: a bispecific antibody for inhibiting cell proliferation induced by IL-5 protein or induced by IL-4Rα. The invention also relates to an isolated nucleic acid molecule encoding the above IL-4R antibodyα, as well as to the vector and cell containing it.
EFFECT: invention is effective for treating a disease induced by IL-4Rα.
11 cl, 9 dwg, 11 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED SINGLE-DOMAIN ANTI-IL-4Rα ANTIBODY AND USE THEREOF | 2021 |
|
RU2836057C2 |
| IL-5 BINDING MOLECULE, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2811518C1 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| IL4R-BINDING ANTIBODIES AND USE THEREOF | 2021 |
|
RU2834713C1 |
| TIGIT ANTIBODIES AND USE THEREOF | 2020 |
|
RU2827445C2 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2840044C1 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2838943C1 |
| KIR3DL3 INHIBITORY RECEPTOR OF IMMUNE SYSTEM AND USE THEREOF | 2020 |
|
RU2827900C1 |
| TETRAVALENT ANTIBODIES TO PSGL-1 AND THEIR APPLICATIONS | 2017 |
|
RU2766000C2 |
| ANTIBODY FOR SPECIFIC BINDING WITH INTERLEUKIN 4 RECEPTOR | 2017 |
|
RU2774446C2 |
